Smith D B, Howell A
Eur J Cancer Clin Oncol. 1987 Apr;23(4):391-4. doi: 10.1016/0277-5379(87)90375-0.
Thirty-eight patients with advanced breast cancer were treated with oral 4-demethoxydaunorubicin in a continuous weekly schedule at a dose of 15 mg/m2/week. Subjective toxicity consisted of mild nausea (grade 1) in 52% with more severe GI side effects (grade 2) in 15%. Three patients developed grade 1 alopecia and there were no episodes of cardiac failure. Significant neutropenia (grade 2/3) only occurred in patients with marrow involvement or widespread bone disease. There was one CR and 5 PRs, an overall response rate of 15.7% (95% confidence limits 6-31%). In addition 6 patients had disease stabilization for at least 6 months. Fourteen patients progressing on 4-demethoxydaunorubicin have received adriamycin 60 mg/m2 21 days. There have been 5 PRs in this group indicating possible non-cross-resistance between these two agents.
38例晚期乳腺癌患者接受口服4-去甲氧基柔红霉素治疗，采用每周一次的持续给药方案，剂量为15mg/m²/周。主观毒性表现为52%的患者出现轻度恶心（1级），15%的患者出现更严重的胃肠道副作用（2级）。3例患者出现1级脱发，未发生心力衰竭事件。显著的中性粒细胞减少（2/3级）仅发生在有骨髓受累或广泛骨病的患者中。有1例完全缓解（CR）和5例部分缓解（PR），总缓解率为15.7%（95%置信区间6-31%）。此外，6例患者疾病稳定至少6个月。14例在4-去甲氧基柔红霉素治疗中病情进展的患者接受了阿霉素60mg/m²，每21天一次。该组中有5例部分缓解，表明这两种药物之间可能不存在交叉耐药性。
